9 8 5 7 4
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.3 Breast Cancer (Dove Med Press)
- 3.4 Clin Epidemiol
- 2.5 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.5 Clin Interv Aging
- 4.7 Drug Des Dev Ther
- 2.7 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.5 Int J Women's Health
- 2.5 Neuropsych Dis Treat
- 2.7 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.3 Ther Clin Risk Manag
- 2.5 J Pain Res
- 2.8 Diabet Metab Synd Ob
- 2.8 Psychol Res Behav Ma
- 3.0 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.7 Risk Manag Healthc Policy
- 4.2 J Inflamm Res
- 2.1 Int J Gen Med
- 4.2 J Hepatocell Carcinoma
- 3.7 J Asthma Allergy
- 1.9 Clin Cosmet Investig Dermatol
- 2.7 J Multidiscip Healthc
IGF2BP2 和 IGFBP3 基因多态性与非小细胞肺癌易感性的关系：华东汉族人群病例对照研究
Authors Chen S, Qiu H, Liu C, Wang Y, Tang W, Kang M
Received 25 March 2018
Accepted for publication 26 May 2018
Published 28 August 2018 Volume 2018:10 Pages 2965—2975
DOI https://doi.org/10.2147/CMAR.S169222
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Cristina Weinberg
Peer reviewer comments 2
Editor who approved publication: Professor Nakshatri
Background: IGF2BP2 and IGFBP3 polymorphisms may be associated with cancer risk.
Methods: With an aim to determine the association of variations in IGF2BP2 and IGFBP3 genes with risk of non-small-cell lung cancer (NSCLC), IGF2BP2 rs1470579 A>C, rs4402960 G>T and IGFBP3 rs2270628 C>T, rs3110697 G>A, and rs6953668 G>A polymorphisms were selected and genotyped in 521 NSCLC patients and 1,030 controls.
Results: We found that there was no difference in IGF2BP2 and IGFBP3 genotype distribution among the NSCLC patients and controls. The stratified analyses suggested that IGF2BP2 rs1470579 A>C polymorphism decreased the risk of NSCLC in some subgroups (female subgroup: CC vs AA: adjusted P =0.032 and CC vs AC/AA: adjusted P =0.028; <60 years subgroup: CC vs AA: adjusted P =0.012 and CC vs AC/AA: adjusted P =0.013; and never drinking subgroup: CC vs AA: adjusted P =0.046 and CC vs AC/AA: adjusted P =0.031). The stratified analyses also found that IGF2BP2 rs4402960 G>T polymorphism decreased the risk of NSCLC in some subgroups (female subgroup: TT vs GG: adjusted P =0.031 and TT vs GT/GG: adjusted P =0.026; <60 subgroup: TT vs GG: adjusted P =0.037 and TT vs GT/GG: adjusted P =0.038; and never drinking subgroup: TT vs GT/GG: adjusted P =0.046). Haplotype analysis indicated Ars1470579Crs2270628Grs3110697Grs4402960Ars6953668 haplotype decreased susceptibility of NSCLC (P =0.007).
Conclusion: Our study suggests that IGF2BP2 rs1470579 A>C, rs4402960 G>T single-nucleotide polymorphisms are candidates for decreased susceptibility to NSCLC among female, <60 years, and never drinking subgroups. In the future, more case–control studies with functional analysis are needed to confirm these preliminary findings.
Keywords: IGFBP3, IGF2BP2, polymorphism, haplotype, risk, NSCLC
